Phio Pharmaceuticals Corp.
Organization details
- Legal name
- Phio Pharmaceuticals Corp.
- Former names
- RXi Pharmaceuticals Corp
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- King of Prussia
- Headquarters state / province
- Pennsylvania
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- PHIO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001533040
- EIN
- 45-3215903
Board of directors
-
Curtis Lockshin · DirectorSince 2023
-
David H. Deming · DirectorSince 2025
-
Geert Cauwenbergh · DirectorSince 2023
-
Jonathan E. Freeman · DirectorSince 2023
-
Patricia A. Bradford · DirectorSince 2023
-
Robert J. Bitterman · Director · Chairman, Pres. & CEOSince 2023
-
Robert L. Ferrara · DirectorSince 2023
-
Ronald Todd Plott · DirectorSince 2026
Chief executives
Director election results
Annual meeting of September 28, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
93.7%
-
96.7%
-
96.9%
-
97.1%
-
97.1%
-
97.3%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $136,990
- 16 purchases by 4 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 11, 2026 | David H. Deming Director | Open-market purchase | +5,200 | $0.84 | $4,358 |
| Nov 10, 2026 | David H. Deming Director | Open-market purchase | +6,800 | $0.84 | $5,709 |
| Nov 9, 2026 | Robert J. Bitterman Director, Officer (Chairman, Pres. & CEO) | Open-market purchase | +25,000 | $0.82 | $20,500 |
| Nov 9, 2026 | Ronald Todd Plott Director | Open-market purchase | +18,300 | $0.83 | $15,189 |
| Sep 29, 2026 | Ronald Todd Plott Director | Open-market purchase | +5,000 | $1.04 | $5,200 |
| Sep 28, 2026 | Robert J. Bitterman Director, Officer (Chairman, Pres. & CEO) | Grant or award | +400,000 | — | — |
| Sep 28, 2026 | Carson Lisa Cabott Officer (Chief Financial Officer) | Grant or award | +108,000 | — | — |
| Sep 28, 2026 | Ronald Todd Plott Director | Grant or award | +17,000 | — | — |
| Sep 28, 2026 | Ronald Todd Plott Director | Open-market purchase | +5,000 | $1.03 | $5,150 |
| Sep 24, 2026 | Patricia A. Bradford Director | Open-market purchase | +6,500 | $1.01 | $6,565 |
| Sep 22, 2026 | Robert J. Bitterman Director, Officer (Chairman, Pres. & CEO) | Open-market purchase | +2,000 | $1.03 | $2,060 |
| Sep 15, 2026 | Patricia A. Bradford Director | Open-market purchase | +12,000 | $1.03 | $12,360 |
| Sep 11, 2026 | Robert J. Bitterman Director, Officer (Chairman, Pres. & CEO) | Shares withheld for tax | −68,550 | $1.03 | $70,607 |
| Sep 11, 2026 | Carson Lisa Cabott Officer (Chief Financial Officer) | Shares withheld for tax | −12,888 | $1.03 | $13,275 |
| Aug 19, 2026 | Ronald Todd Plott Director | Open-market purchase | +15,000 | $1.14 | $17,100 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Phio Pharmaceuticals Corp.
Who is the CEO of Phio Pharmaceuticals Corp.?
Robert J. Bitterman is Phio Pharmaceuticals Corp.'s President & CEO.
How many directors are on Phio Pharmaceuticals Corp.'s board?
Phio Pharmaceuticals Corp.'s board has 8 directors: Curtis Lockshin, David H. Deming, Geert Cauwenbergh, Jonathan E. Freeman, Patricia A. Bradford, Robert J. Bitterman, Robert L. Ferrara and Ronald Todd Plott.
Are Phio Pharmaceuticals Corp. insiders buying or selling shares?
Over the last 12 months, Phio Pharmaceuticals Corp. insiders bought $136,990 of shares in 16 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="phio-pharmaceuticals-corp"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.